内容紹介
Summary
From January 2016 through December 2017, 18 patients received paclitaxel plus ramucirumab combination therapy and 1 patient received ramucirumab monotherapy. Thus, a total of 19 patients were analyzed in terms of both therapeutic effect and adverse events. The response evaluation of the targeted lesion was as follows; CR: 0, PR: 1, SD: 16, PD: 2. The median of overall survival and progression-free survival of the combination therapy was 9.9 months and 4.2 months, respectively. Although more than half of the patients were enforced after tertiary therapy in our department, the therapeutic effect of paclitaxel plus ramucirumab combination therapy was considerably satisfactory. Neutropenia as an adverse event was observed in 13(68.4%)out of 19 patients, and 8 patients(42.1%)had neutropenia greater than Grade 3. Non-hematologic toxicity was observed in 17 cases(89.5%), and anorexia, nausea, diarrhea, dysgeusia, peripheral neuropathy, hair loss, and fatigue were determined to be either Grade 1 or 2. Alternatively, 1 patient developed Grade 3 interstitial pneumonia, and 3 patients(15.8%)had complicated Grade 3 high blood pressure. Only 2 patients who had severe adverse events, one was interstitial pneumonia and the other was high blood pressure, discontinued paclitaxel plus ramucirumab combination therapy.
要旨
2016年1月～2017年12月までの2年間に当科でパクリタキセル+ラムシルマブ併用療法を18例に,ラムシルマブ単独療法を1例に施行したので,それらを集計・分析し,治療成績,有害事象,課題などについて検討した。臨床効果は,CR: 0,PR: 1,SD: 16,PD: 2であり,併用療法の全生存期間中央値は9.9か月,無増悪生存期間中央値は4.2か月であった。しかし(胃癌治療ガイドラインでは二次治療として推奨されているが),半数以上が三次治療以降として施行されていた。有害事象は好中球減少が対象症例19例中13例(68.4%)に認められ,Grade 3以上も8例(42.1%)と高率であった。非血液毒性は17例(89.5%)に認められ,Grade 1,2では食欲不振,悪心,下痢,味覚異常,末梢神経障害,脱毛,疲労などが,Grade 3以上では間質性肺炎1例(5.3%),高血圧が3例(15.8%)であった。また,有害事象で治療を中止したのは,間質性肺炎の1例と高血圧の1例の計2例であった。
目次
From January 2016 through December 2017, 18 patients received paclitaxel plus ramucirumab combination therapy and 1 patient received ramucirumab monotherapy. Thus, a total of 19 patients were analyzed in terms of both therapeutic effect and adverse events. The response evaluation of the targeted lesion was as follows; CR: 0, PR: 1, SD: 16, PD: 2. The median of overall survival and progression-free survival of the combination therapy was 9.9 months and 4.2 months, respectively. Although more than half of the patients were enforced after tertiary therapy in our department, the therapeutic effect of paclitaxel plus ramucirumab combination therapy was considerably satisfactory. Neutropenia as an adverse event was observed in 13(68.4%)out of 19 patients, and 8 patients(42.1%)had neutropenia greater than Grade 3. Non-hematologic toxicity was observed in 17 cases(89.5%), and anorexia, nausea, diarrhea, dysgeusia, peripheral neuropathy, hair loss, and fatigue were determined to be either Grade 1 or 2. Alternatively, 1 patient developed Grade 3 interstitial pneumonia, and 3 patients(15.8%)had complicated Grade 3 high blood pressure. Only 2 patients who had severe adverse events, one was interstitial pneumonia and the other was high blood pressure, discontinued paclitaxel plus ramucirumab combination therapy.
要旨
2016年1月～2017年12月までの2年間に当科でパクリタキセル+ラムシルマブ併用療法を18例に,ラムシルマブ単独療法を1例に施行したので,それらを集計・分析し,治療成績,有害事象,課題などについて検討した。臨床効果は,CR: 0,PR: 1,SD: 16,PD: 2であり,併用療法の全生存期間中央値は9.9か月,無増悪生存期間中央値は4.2か月であった。しかし(胃癌治療ガイドラインでは二次治療として推奨されているが),半数以上が三次治療以降として施行されていた。有害事象は好中球減少が対象症例19例中13例(68.4%)に認められ,Grade 3以上も8例(42.1%)と高率であった。非血液毒性は17例(89.5%)に認められ,Grade 1,2では食欲不振,悪心,下痢,味覚異常,末梢神経障害,脱毛,疲労などが,Grade 3以上では間質性肺炎1例(5.3%),高血圧が3例(15.8%)であった。また,有害事象で治療を中止したのは,間質性肺炎の1例と高血圧の1例の計2例であった。